Pharmacologic management of non-neurogenic functional obstruction in women

被引:8
|
作者
Cohn, Joshua A. [1 ]
Brown, Elizabeth T. [1 ]
Reynolds, W. Stuart [1 ]
Kaufman, Melissa R. [1 ]
Dmochowski, Roger R. [1 ]
机构
[1] Univ Med Ctr, Dept Urol Surg, 1302A Med Ctr North, Nashville, TN 37203 USA
关键词
Women; urinary retention; functional obstruction; voiding dysfunction; primary bladder neck obstruction; pharmacology; BLADDER NECK OBSTRUCTION; URINARY-TRACT SYMPTOMS; BOTULINUM-A TOXIN; BENIGN PROSTATIC HYPERPLASIA; PELVIC FLOOR DYSFUNCTION; PLACEBO-CONTROLLED TRIAL; VOIDING DYSFUNCTION; SACRAL NEUROMODULATION; URETHRAL SPHINCTER; OUTLET OBSTRUCTION;
D O I
10.1080/17425255.2016.1178239
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Impaired bladder emptying in women without neurologic disease may be related to urethral obstruction and/or impaired bladder contractility. Mechanical obstruction generally requires surgical management and options are limited for impaired bladder contractility. However, functional obstruction from voiding dysfunction or primary bladder neck obstruction may present an opportunity for pharmacologic intervention. Areas covered: In this review, the authors extensively reviewed available literature regarding the use of off-label medications for functional bladder outlet obstruction in women. In addition, side effect profiles and pharmacology of these medications determined from on-label indications are reviewed. Specific medications reviewed include vaginal diazepam, baclofen, urethral botulinum toxin injection, and alpha-adrenergic blockers. Expert opinion: Alpha-blockers in particular have demonstrated promise in women with demonstrable or suspected bladder outlet obstruction with side effect profiles similar to those observed in men. However, lack of quality data hinders informed decision making with alpha-blockers or any of the other agents studied in women with non-neurogenic functional outlet obstruction. In the absence of well-designed, placebo-controlled multi-institutional trials, those prescribing these medications must be aware of special considerations and side effects associated with relatively unfamiliar treatments in the context of uncertain benefit.
引用
收藏
页码:657 / 667
页数:11
相关论文
共 50 条
  • [31] Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms
    Serati, Maurizio
    Andersson, Karl-Erik
    Dmochowski, Roger
    Agro, Enrico Finazzi
    Heesakkers, John
    Iacovelli, Valerio
    Novara, Giacomo
    Khullar, Vik
    Chapple, Christopher
    EUROPEAN UROLOGY, 2019, 75 (01) : 129 - 168
  • [32] European Association of Urology Guidelines on the Diagnosis and Management of Female Non-neurogenic Lower Urinary Tract Symptoms. Part 1: Diagnostics, Overactive Bladder, Stress Urinary Incontinence, and Mixed Urinary Incontinence
    Nambiar, Arjun K.
    Arlandis, Salvador
    Bo, Kari
    Cobussen-Boekhorst, Hanny
    Costantini, Elisabetta
    de Heide, Monica
    Farag, Fawzy
    Groen, Jan
    Karavitakis, Markos
    Lapitan, Marie Carmela
    Manso, Margarida
    Arteaga, Serenella Monagas
    Riogh, Aisling Nic An
    O'Connor, Eabhann
    Omar, Muhammad Imran
    Peyronnet, Benoit
    Phe, Veronique
    Sakalis, Vasileios, I
    Sihra, Neha
    Tzelves, Lazaros
    van Poelgeest-Pomfret, Mary-Lynne
    van den Bos, Tine W. L.
    van der Vaart, Huub
    Harding, Christopher K.
    EUROPEAN UROLOGY, 2022, 82 (01) : 49 - 59
  • [33] Efficacy of holmium laser enucleation of the prostate (HoLEP) in men with bladder outlet obstruction (BOO) and non-neurogenic bladder dysfunction
    Pyun, Jong Hyun
    Kang, Sung Gu
    Kang, Seok Ho
    Cheon, Jun
    Kim, Je Jong
    Lee, Jeong Gu
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2017, 33 (09) : 458 - 463
  • [34] Functional changes during the voiding phase in males with non-neurogenic detrusor underactivity undergoing bladder catheterization
    Virseda-Chamorro, Miguel
    Salinas-Casado, Jesus
    Mendez-Rubio, Santiago
    Barroso Manso, Alvaro
    Esteban-Fuertes, Manuel
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (06): : 564 - 569
  • [35] Efficacy of tolterodine as a first-line treatment for non-neurogenic voiding dysfunction in children
    Ayan, S
    Kaya, K
    Topsakal, K
    Kilicarslan, H
    Gokce, G
    Gultekin, Y
    BJU INTERNATIONAL, 2005, 96 (03) : 411 - +
  • [36] Follow-up and evaluation of non-neurogenic OAB treatments
    Phe, V
    Game, X.
    PROGRES EN UROLOGIE, 2020, 30 (14): : 931 - 937
  • [37] Non-neurogenic Chronic Urinary Retention: What Are We Treating?
    John T. Stoffel
    Current Urology Reports, 2017, 18
  • [38] Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark
    Buchter, Marie Lynge
    Kjellberg, Jakob
    Ibsen, Rikke
    Sternhufvud, Catarina
    Petersen, Birte
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (04) : 409 - 418
  • [39] Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction
    Utomo, Elaine
    Groen, Jan
    Blok, Bertil F. M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (05):
  • [40] Analisys of non-neurogenic rower urinary tract dysfunction patterns controlled in a Pediatric urodynamic unit
    Miguez-Fortes, Lorena
    Somoza-Argibay, Ivan
    Casal-Beloy, Isabel
    Garcia-Gonzalez, Miriam
    Dargallo-Carbonell, Teresa
    ARCHIVOS ESPANOLES DE UROLOGIA, 2019, 72 (01): : 45 - 53